Anatara Lifesciences Ltd (ASX:ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.
Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R).
Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.
Queensland Bauxite Ltd (ASX:QBL) provides the Company's Quarterly Activities Report.
Nanollose Limited (ASX:NC6) is pleased to provide its Appendix 4C Cash flow Statement for the quarter ending 31 March 2018, together with the following operational update.
Nanollose Limited (ASX:NC6) advises that it has completed the mailing of the Prospectus lodged with ASIC and ASX dated 16 April 2018. The Company confirms that the Offer is now open.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.
